SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.

This analysis showed that patients with LUAD with high YES1 expression tended to have a higher number of Treg cells, although this difference did not reach statistical significance (p=0.055, figure 1I ).

also in 111,027 other papers

In the 393P subcutaneous adenocarcinoma model, treatment with dasatinib resulted in a highly significant reduction in tumor volume (~70% at day 35 postcell injection with respect to controls), whereas anti-PD-1 showed a modest decrease (~24%) ( figure 3A ).

also in 132,142 other papers